240 related articles for article (PubMed ID: 30362181)
41. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
Pettus J; Gill J; Paranjape S; Stewart J; Malla S; Edelman S; Bergenstal RM; Bode B
Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
[TBL] [Abstract][Full Text] [Related]
42. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
43. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
44. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
[TBL] [Abstract][Full Text] [Related]
45. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial.
Koivisto V; Cleall S; Pontiroli AE; Giugliano D
Diabetes Obes Metab; 2011 Dec; 13(12):1149-57. PubMed ID: 21819517
[TBL] [Abstract][Full Text] [Related]
46. Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.
Bolli GB; Songini M; Trovati M; Del Prato S; Ghirlanda G; Cordera R; Trevisan R; Riccardi G; Noacco C
Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):571-9. PubMed ID: 18676131
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
[TBL] [Abstract][Full Text] [Related]
48. Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice.
Carral San Laureano F; Tomé Fernández-Ladreda M; Jiménez Millán AI; García Calzado C; Ayala Ortega MDC
J Investig Med; 2021 Jun; 69(5):983-988. PubMed ID: 33771843
[TBL] [Abstract][Full Text] [Related]
49. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.
Rosenstock J; Aronson R; Grunberger G; Hanefeld M; Piatti P; Serusclat P; Cheng X; Zhou T; Niemoeller E; Souhami E; Davies M;
Diabetes Care; 2016 Nov; 39(11):2026-2035. PubMed ID: 27527848
[TBL] [Abstract][Full Text] [Related]
50. The outcome of care in people with type 1 diabetes after switching to insulin glargine-based regimens in a real-life setting: a long-term observational study.
Dąbrowski M
Int J Clin Pract; 2014 Aug; 68(8):1020-8. PubMed ID: 25040042
[TBL] [Abstract][Full Text] [Related]
51. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
[TBL] [Abstract][Full Text] [Related]
52. [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].
Bohn B; Bramlage P; Wagner C; Kaltheuner M; Welp R; Sziegoleit S; Zimmermann A; Reuter HM; Hummel M; Gloyer J; Holl RW; Danne T
Wien Med Wochenschr; 2018 Nov; 168(15-16):415-422. PubMed ID: 28828553
[TBL] [Abstract][Full Text] [Related]
53. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
Hemmingsen B; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
[TBL] [Abstract][Full Text] [Related]
54. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
[TBL] [Abstract][Full Text] [Related]
55. Higher insulin detemir doses are required for the similar glycemic control: comparison of insulin detemir and glargine in children with type 1 diabetes mellitus.
Abalı S; Turan S; Atay Z; Güran T; Haliloğlu B; Bereket A
Pediatr Diabetes; 2015 Aug; 16(5):361-6. PubMed ID: 25039448
[TBL] [Abstract][Full Text] [Related]
56. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
Hurren KM; O'Neill JL
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
[TBL] [Abstract][Full Text] [Related]
57. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
[TBL] [Abstract][Full Text] [Related]
59. Insulin pump use in pregnancy is associated with lower HbA1c without increasing the rate of severe hypoglycaemia or diabetic ketoacidosis in women with type 1 diabetes.
Kallas-Koeman MM; Kong JM; Klinke JA; Butalia S; Lodha AK; Lim KI; Duan QM; Donovan LE
Diabetologia; 2014 Apr; 57(4):681-9. PubMed ID: 24434960
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
